This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Generic drugmakers file reply supporting dismissing states' US antitrust claims

( February 14, 2025, 22:05 GMT | Official Statement) -- MLex Summary: Sun Pharmaceutical, Lannett, Mylan Pharmaceuticals and other generic drugmakers filed a reply in support of their motion to dismiss US antitrust claims filed by state plaintiffs, arguing that they are impermissibly split among multiple complaints. “The States cite no authority that would allow them to plead the same overarching agreement in multiple complaints to expand the scope of joint and several liability for each subsequent complaint. In fact, their cited authorities state the opposite,” they said.See attached file. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login